Origin Endoscopy has developed a groundbreaking multipurpose hydrogel that incorporates sustained-release epinephrine microparticles, specifically designed for ultrafast bio-adhesion and submucosal injection. This innovative technology aims to enhance the management of gastrointestinal (GI) bleeding during various endoscopic procedures by providing controlled and prolonged hemostatic effects. The hydrogel addresses the limitations of current products used for treating GI bleeding, offering a durable solution that can be utilized by endoscopists to effectively manage a range of bleeding conditions and facilitate the healing process at the injury site.

The company was established through a collaboration between inventors from prestigious institutions such as Johns Hopkins Medicine and the University of Maryland, alongside commercial experts in the interventional endoscopy field. This partnership has led to the creation of a unique gel that stands out in the market, aiming to elevate the therapeutic standard of care for GI bleeding. With a team composed of leading endoscopists, researchers, and commercial specialists, Origin Endoscopy is committed to advancing treatment options and improving patient outcomes in the realm of gastrointestinal health.

United States

Origin Endoscopy was formed through a collaboration of inventors from Johns Hopkins Medicine and the University of Maryland, and commercial experts in the interventional endoscopy space. 

Their primary technology is designed to control and extend the hemostatic effects of gastrointestinal (GI) bleeding during a variety of endoscopy procedures.

Origin Endoscopy

Company Details